<DOC>
	<DOCNO>NCT02655705</DOCNO>
	<brief_summary>This study evaluate performance objective psoriasis severity assessment tool compare subjective assessment tool assessment improvement psoriasis oral cyclosporine A methotrexate treatment .</brief_summary>
	<brief_title>Comparison Study Psoriasis Severity Assessment Tools</brief_title>
	<detailed_description>Patients moderate-to-severe psoriasis randomly assign treatment 16 week either cyclosporine A ( 20 patient ; male 200 mg/day , female 150 mg/day ) methotrexate ( 20 patient ; initial dose 10 mg/week , increase 15 mg/week ) . The primary outcome compare difference conventional subjective Psoriasis Area Severity Index ( PASI ) objective PASI use Colorimeter 2 , 4 , 8 , 12 , 16 week treatment . The secondary outcome difference cyclosporine methotrexate treatment psoriasis , evaluate clinical efficacy side effect .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>Present chronic plaque psoriasis base clinical diagnosis Have &gt; 5 % body surface area involvement screening Are candidate systemic therapy Are male female patient 18 year old Have give write informed consent approve Institutional Review Board Have predominant pattern pustular , erythrodermic , guttate form psoriasis Have systemic nonbiologic psoriasis therapy ( include neotigason , cyclosporine , methotrexate ) within 4 week prior baseline Have etanercept within 4 week prior baseline Have adalimumab infliximab within 8 week prior baseline Have ustekinumab within 16 week prior baseline Presence significant hepatic renal disorder Have uncontrolled arterial hypertension Are woman lactate , breastfeed plan pregnancy Have condition precludes follow complete protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Cyclosporine</keyword>
	<keyword>Methotrexate</keyword>
</DOC>